Jacob Alexander Sloane, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis, Relapsing-Remitting | 12 | 2024 | 556 | 3.110 |
Why?
|
| Multiple Sclerosis | 25 | 2024 | 3204 | 3.050 |
Why?
|
| Immunologic Factors | 6 | 2024 | 1588 | 1.650 |
Why?
|
| Herpes Zoster | 2 | 2024 | 251 | 1.510 |
Why?
|
| Myelin Sheath | 9 | 2023 | 652 | 1.420 |
Why?
|
| Lymphopenia | 2 | 2024 | 280 | 1.380 |
Why?
|
| Immunosuppressive Agents | 5 | 2024 | 4166 | 0.890 |
Why?
|
| Oligodendroglia | 6 | 2013 | 536 | 0.850 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2021 | 38 | 0.760 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 7 | 2024 | 254 | 0.750 |
Why?
|
| JC Virus | 2 | 2018 | 87 | 0.640 |
Why?
|
| Drug Substitution | 2 | 2024 | 296 | 0.630 |
Why?
|
| Neuromyelitis Optica | 1 | 2022 | 259 | 0.600 |
Why?
|
| Neuralgia | 1 | 2023 | 600 | 0.570 |
Why?
|
| Lymphocyte Count | 3 | 2024 | 780 | 0.530 |
Why?
|
| Biotin | 1 | 2016 | 253 | 0.510 |
Why?
|
| Endometriosis | 1 | 2023 | 874 | 0.500 |
Why?
|
| Bariatric Surgery | 1 | 2023 | 1005 | 0.440 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2024 | 1860 | 0.380 |
Why?
|
| Wiskott-Aldrich Syndrome Protein Family | 2 | 2007 | 35 | 0.370 |
Why?
|
| Meninges | 2 | 2024 | 197 | 0.370 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 2622 | 0.350 |
Why?
|
| Cerebral Cortex | 8 | 2024 | 5761 | 0.330 |
Why?
|
| Receptors, GABA | 2 | 2024 | 305 | 0.320 |
Why?
|
| Nerve Degeneration | 3 | 2017 | 748 | 0.320 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2010 | 348 | 0.300 |
Why?
|
| Myosin Type V | 1 | 2007 | 33 | 0.300 |
Why?
|
| Antibodies, Viral | 1 | 2018 | 3143 | 0.280 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2018 | 133 | 0.280 |
Why?
|
| Fatigue | 2 | 2024 | 1544 | 0.280 |
Why?
|
| Hyaluronic Acid | 1 | 2010 | 482 | 0.270 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2007 | 435 | 0.260 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 590 | 0.260 |
Why?
|
| Myosin Heavy Chains | 1 | 2007 | 402 | 0.260 |
Why?
|
| Disability Evaluation | 4 | 2023 | 1826 | 0.250 |
Why?
|
| Registries | 1 | 2021 | 8469 | 0.250 |
Why?
|
| Disease Progression | 4 | 2023 | 13502 | 0.240 |
Why?
|
| Demyelinating Diseases | 2 | 2018 | 351 | 0.240 |
Why?
|
| CD4-CD8 Ratio | 1 | 2024 | 114 | 0.240 |
Why?
|
| Morphogenesis | 2 | 2007 | 740 | 0.240 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2024 | 36290 | 0.210 |
Why?
|
| Calpain | 1 | 2003 | 145 | 0.200 |
Why?
|
| Nerve Fibers, Myelinated | 3 | 2015 | 952 | 0.200 |
Why?
|
| Hospitalization | 1 | 2021 | 10790 | 0.190 |
Why?
|
| Cladribine | 1 | 2021 | 34 | 0.190 |
Why?
|
| Adult | 24 | 2024 | 219994 | 0.190 |
Why?
|
| Aging | 4 | 2003 | 8651 | 0.190 |
Why?
|
| Toluidines | 1 | 2020 | 21 | 0.180 |
Why?
|
| Crotonates | 1 | 2020 | 21 | 0.180 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2021 | 45 | 0.180 |
Why?
|
| Female | 32 | 2024 | 391270 | 0.170 |
Why?
|
| Actins | 1 | 2007 | 2049 | 0.170 |
Why?
|
| Humans | 42 | 2024 | 760621 | 0.170 |
Why?
|
| Peptide Hydrolases | 1 | 2003 | 623 | 0.170 |
Why?
|
| Male | 31 | 2024 | 359744 | 0.170 |
Why?
|
| Middle Aged | 21 | 2024 | 220352 | 0.170 |
Why?
|
| Cerebrum | 1 | 2021 | 132 | 0.170 |
Why?
|
| Comorbidity | 2 | 2024 | 10551 | 0.150 |
Why?
|
| New England | 1 | 2021 | 1050 | 0.150 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2000 | 550 | 0.150 |
Why?
|
| Neurobehavioral Manifestations | 1 | 1997 | 10 | 0.150 |
Why?
|
| Nitrates | 1 | 1999 | 264 | 0.150 |
Why?
|
| Positron-Emission Tomography | 4 | 2024 | 6465 | 0.150 |
Why?
|
| Stem Cells | 1 | 2010 | 3523 | 0.140 |
Why?
|
| HIV-2 | 1 | 2017 | 156 | 0.140 |
Why?
|
| Nerve Fibers | 1 | 2000 | 708 | 0.130 |
Why?
|
| Risk Factors | 5 | 2024 | 74359 | 0.130 |
Why?
|
| Brain | 11 | 2024 | 26951 | 0.130 |
Why?
|
| Hematologic Tests | 1 | 2016 | 238 | 0.130 |
Why?
|
| Immunoglobulins | 1 | 2018 | 859 | 0.120 |
Why?
|
| Social Adjustment | 1 | 2017 | 632 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 15840 | 0.120 |
Why?
|
| Thalamus | 2 | 2020 | 1041 | 0.120 |
Why?
|
| Immunity | 1 | 2021 | 998 | 0.120 |
Why?
|
| Risk Assessment | 1 | 2016 | 24123 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2019 | 3340 | 0.120 |
Why?
|
| Microglia | 2 | 2023 | 1351 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2023 | 80372 | 0.110 |
Why?
|
| Macaca mulatta | 4 | 2003 | 2316 | 0.110 |
Why?
|
| Plaque, Amyloid | 1 | 1997 | 758 | 0.110 |
Why?
|
| Astrocytes | 1 | 2000 | 1338 | 0.100 |
Why?
|
| Weight Loss | 1 | 2023 | 2686 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2023 | 41335 | 0.100 |
Why?
|
| Glucuronidase | 1 | 2013 | 202 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2013 | 8158 | 0.090 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2023 | 4353 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 2852 | 0.090 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2010 | 135 | 0.090 |
Why?
|
| Mortality | 1 | 2021 | 2916 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 4407 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 4550 | 0.080 |
Why?
|
| Vitamin D | 1 | 2023 | 3291 | 0.080 |
Why?
|
| Vesicle-Associated Membrane Protein 2 | 1 | 2007 | 17 | 0.080 |
Why?
|
| Immunity, Innate | 2 | 2011 | 3047 | 0.080 |
Why?
|
| Recurrence | 2 | 2021 | 8482 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2021 | 8555 | 0.080 |
Why?
|
| Executive Function | 1 | 2016 | 1374 | 0.070 |
Why?
|
| Phagocytes | 1 | 2009 | 296 | 0.070 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2007 | 98 | 0.070 |
Why?
|
| Adaptation, Psychological | 1 | 2017 | 2628 | 0.070 |
Why?
|
| Growth Inhibitors | 1 | 2007 | 378 | 0.070 |
Why?
|
| Inflammation | 3 | 2019 | 10756 | 0.070 |
Why?
|
| Rats | 4 | 2013 | 23711 | 0.070 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2006 | 100 | 0.070 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2010 | 581 | 0.070 |
Why?
|
| Nerve Net | 1 | 2018 | 2261 | 0.060 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 795 | 0.060 |
Why?
|
| Emotions | 1 | 2017 | 2734 | 0.060 |
Why?
|
| Axons | 2 | 2017 | 1673 | 0.060 |
Why?
|
| Animals | 12 | 2013 | 167963 | 0.060 |
Why?
|
| Necrosis | 1 | 2009 | 1612 | 0.060 |
Why?
|
| Central Nervous System | 2 | 2009 | 1334 | 0.060 |
Why?
|
| Central Nervous System Diseases | 1 | 2009 | 521 | 0.060 |
Why?
|
| Neurites | 1 | 2006 | 390 | 0.060 |
Why?
|
| Neuroglia | 1 | 2010 | 944 | 0.060 |
Why?
|
| Pyrimidines | 1 | 2016 | 3016 | 0.060 |
Why?
|
| Neural Inhibition | 1 | 2007 | 589 | 0.060 |
Why?
|
| 2',3'-Cyclic-Nucleotide Phosphodiesterases | 1 | 2003 | 6 | 0.050 |
Why?
|
| Uric Acid | 1 | 2009 | 806 | 0.050 |
Why?
|
| Age Factors | 1 | 2019 | 18416 | 0.050 |
Why?
|
| Acetamides | 1 | 2024 | 256 | 0.050 |
Why?
|
| Ligands | 1 | 2009 | 3276 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2016 | 12427 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3085 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3205 | 0.050 |
Why?
|
| Apoptosis | 2 | 2009 | 9501 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2009 | 1726 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2019 | 12914 | 0.050 |
Why?
|
| Cerebral Ventricles | 1 | 2024 | 542 | 0.050 |
Why?
|
| Clinical Trials, Phase IV as Topic | 1 | 2021 | 29 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2010 | 2533 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2013 | 8313 | 0.050 |
Why?
|
| Tablets | 1 | 2021 | 149 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2013 | 18957 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2007 | 2913 | 0.040 |
Why?
|
| Hydroxybutyrates | 1 | 2020 | 79 | 0.040 |
Why?
|
| Quality of Life | 2 | 2021 | 13308 | 0.040 |
Why?
|
| Blotting, Western | 3 | 2006 | 5039 | 0.040 |
Why?
|
| Gliosis | 1 | 2000 | 244 | 0.040 |
Why?
|
| Aged | 7 | 2024 | 169152 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2011 | 23376 | 0.040 |
Why?
|
| Prospective Studies | 6 | 2021 | 54303 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2000 | 555 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 9530 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 1999 | 630 | 0.040 |
Why?
|
| Mice | 6 | 2013 | 81208 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 1999 | 393 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2018 | 22053 | 0.040 |
Why?
|
| Austria | 1 | 2017 | 206 | 0.040 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2017 | 61 | 0.040 |
Why?
|
| Bell Palsy | 1 | 2017 | 39 | 0.040 |
Why?
|
| Serum Amyloid A Protein | 1 | 1997 | 127 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2009 | 2477 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2013 | 14372 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 1999 | 908 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2021 | 1722 | 0.030 |
Why?
|
| Gadolinium | 1 | 2020 | 959 | 0.030 |
Why?
|
| Family Relations | 1 | 2017 | 318 | 0.030 |
Why?
|
| Atrophy | 1 | 2020 | 1627 | 0.030 |
Why?
|
| Nitriles | 1 | 2020 | 956 | 0.030 |
Why?
|
| Tyrosine | 1 | 1999 | 1438 | 0.030 |
Why?
|
| Apolipoproteins | 1 | 1997 | 320 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2020 | 4048 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2010 | 22023 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2017 | 633 | 0.030 |
Why?
|
| Anisotropy | 1 | 2017 | 1278 | 0.030 |
Why?
|
| Brain Chemistry | 1 | 1997 | 959 | 0.030 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 1999 | 1110 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 3804 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2021 | 4035 | 0.030 |
Why?
|
| Pyridines | 1 | 2024 | 2879 | 0.030 |
Why?
|
| Young Adult | 4 | 2021 | 58741 | 0.030 |
Why?
|
| Interferon-beta | 1 | 2014 | 345 | 0.030 |
Why?
|
| Polyomavirus Infections | 1 | 2014 | 194 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 65017 | 0.020 |
Why?
|
| Self Concept | 1 | 2017 | 1039 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2013 | 333 | 0.020 |
Why?
|
| Psychomotor Performance | 1 | 1999 | 1878 | 0.020 |
Why?
|
| HIV Infections | 1 | 2017 | 17165 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2018 | 8950 | 0.020 |
Why?
|
| Neurons | 2 | 2007 | 9426 | 0.020 |
Why?
|
| Optic Nerve | 1 | 2013 | 567 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2018 | 6238 | 0.020 |
Why?
|
| Cell Count | 1 | 2013 | 1835 | 0.020 |
Why?
|
| Corpus Callosum | 1 | 2013 | 749 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2014 | 2362 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2014 | 2194 | 0.020 |
Why?
|
| Alzheimer Disease | 2 | 1999 | 8547 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 39261 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 2782 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2014 | 3157 | 0.020 |
Why?
|
| Chick Embryo | 1 | 2007 | 981 | 0.020 |
Why?
|
| Neural Stem Cells | 1 | 2013 | 884 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2006 | 251 | 0.020 |
Why?
|
| Amyloid beta-Peptides | 1 | 1997 | 3832 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1997 | 11071 | 0.010 |
Why?
|
| Sex Factors | 1 | 2017 | 10547 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2006 | 1705 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2017 | 3976 | 0.010 |
Why?
|
| Cell Survival | 1 | 2013 | 5797 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2006 | 1900 | 0.010 |
Why?
|
| Cognition | 1 | 1999 | 6957 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2006 | 2672 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2006 | 1674 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8624 | 0.010 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 1999 | 179 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2006 | 2488 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1999 | 1744 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 10181 | 0.010 |
Why?
|
| Time Factors | 2 | 2014 | 40165 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2006 | 3604 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 58995 | 0.010 |
Why?
|
| Child | 1 | 2021 | 79806 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 6131 | 0.010 |
Why?
|
| Transfection | 1 | 1999 | 5781 | 0.010 |
Why?
|
| United States | 1 | 2017 | 72461 | 0.010 |
Why?
|